The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Isis Pharmaceuticals Inc

Nasdaq: ISIS
Last

(U.S.) $63.18

Today's change0.00 0.00%
Updated April 1 4:00 PM EDT. Delayed by at least 15 minutes.
 

Isis Pharmaceuticals Inc

Nasdaq: ISIS
Last

(U.S.) $63.18

Today's change0.00 0.00%
Updated April 1 4:00 PM EDT. Delayed by at least 15 minutes.

Isis Pharmaceuticals Inc closed at (U.S.)$63.18.

Over the last five days, shares have gained 1.27%, but are currently unchanged over the last year to date. Shares have outperformed the S&P 500 by 36.57% during the last year.

Key company metrics

  • Open(U.S.) $63.23
  • Previous close(U.S.) $63.18
  • High(U.S.) $64.00
  • Low(U.S.) $60.68
  • Bid / Ask-- / --
  • YTD % change+2.33%
  • Volume2,721,010
  • Average volume (10-day)3,881,228
  • Average volume (1-month)3,008,349
  • Average volume (3-month)3,345,406
  • 52-week range(U.S.) $22.25 to (U.S.) $77.80
  • Beta1.49
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.33
Updated April 1 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-18.20%

Isis Pharmaceuticals Inc has a net profit margin of -18.20%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.27%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue85445728
Total other revenue--------
Total revenue85445728
Gross profit17-17-2-25
Total cost of revenue68615953
Total operating expense83666458
Selling / general / administrative7444
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)8------
Other operating expenses, total--------
Operating income2-21-7-30
Interest income (expense), net non-operating-7-5-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax16-25-11-34
Income after tax31-27-12-31
Income tax, total-1511-2
Net income31-27-12-31
Total adjustments to net income--------
Net income before extra. items31-27-12-31
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items31-27-12-31
Inc. avail. to common incl. extra. items31-27-12-31
Diluted net income31-27-12-31
Dilution adjustment------0
Diluted weighted average shares118118118117
Diluted EPS excluding extraordinary itemsvalue per share0.26-0.23-0.10-0.27
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.31-0.23-0.10-0.27